Rapid weight loss with medications such as semaglutide and tirzepatide can lead to meaningful changes in body weight, appetite, blood sugar, and cardiometabolic health
This review highlights epidemiology, risk factors, genetics, pathogenesis, clinical manifestations, diagnostic methods, epigenetic mechanisms, and recent therapeutic advances
As stated before, glutathione is the most abundant antioxidant in the cell, with a key role in ROS scavenging in cancer cells
Strength improvements indicate muscle and tendon recovering
And it should, because safety data often matters more than efficacy data for individual treatment decisions
Individuals who may warrant closer monitoring include: Those with a personal or family history of depression , anxiety, or other mood disorders People who have previously experienced mood changes on other weight-loss medications or GLP-1-based therapies Individuals with eating disorders or a complex relationship with food , for whom appetite suppression may have psychological implications (see NICE guideline NG69: Eating disorders: recognition and treatment) [10] Those experiencing significant life stressors alongside starting a new treatment People with poorly controlled type 2 diabetes , where fluctuating blood glucose levels both hypoglycaemia and hyperglycaemia can independently affect mood, concentration, and emotional wellbeing It is also worth acknowledging that obesity itself is associated with higher rates of depression and anxiety, and that the psychological experience of rapid body weight change whether positive or negative can be emotionally complex
